Total cohort (n = 184)
|
Baseline SOFA without renal component
|
1.16 [1.01–1.33]
|
0.02
|
1.16 [1.01–1.32]
|
0.03
|
Baseline urine output (ml/kg/h)
|
0.28 [0.16–0.49]
|
< 0.001
|
0.32 [0.19–0.56]
|
< 0.001
|
Baseline SCr concentration* (μmol/l)
|
1.30 [1.08–1.56]
|
0.005
|
1.30 [1.08–1.56]
|
0.006
|
Baseline [TIMP-2]*[IGFBP7]
| | |
1.04 [0.98–1.11]
|
0.2
|
Norepinephrine dose at inclusion (μg/kg/min)
|
2.75 [1.22–6.20]
|
0.01
|
2.67 [1.19–6.03]
|
0.02
|
AUROC
|
0.81 [0.74–0.86]
|
0.81 [0.74–0.86]
|
Brier score#
|
0.18
|
0.17
|
Moderate to severe AKI (n = 90)
|
Baseline SOFA without renal component
|
1.37 [1.09–1.73]
|
0.008
|
1.39 [1.09–1.76]
|
0.007
|
Baseline urine output (ml/kg/h)
|
0.18 [0.07–0.46]
|
< 0.001
|
0.19 [0.07–0.49]
|
< 0.001
|
Baseline SCr concentration* (μmol/l)
|
1.22 [0.95–1.58]
|
0.1
|
1.23 [0.95–1.59]
|
0.1
|
Baseline [TIMP-2]*[IGFBP7]
| | |
1.01 [0.95–1.08]
|
0.7
|
Norepinephrine dose at inclusion (μg/kg/min)
|
4.55 [1.12–18.45]
|
0.03
|
4.32 [1.07–17.46]
|
0.04
|
AUROC
|
0.86 [0.77–0.92]
|
0.86 [0.77–0.92]
|
Brier score#
|
0.19
|
0.19
|